STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Monthly information on share capital and company voting rights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of 09/30/2025. The company reports a total number of shares of 100,325,229 and a total number of voting rights of 89,413,272. The disclosure follows Article 223-16 of the General Regulation of the French financial markets authority and lists investor and media contacts for further information.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 16 Alerts

+20.13% News Effect
$4.59 Close Price
+$56M Valuation Impact
$332M Market Cap
2.2x Rel. Volume

On the day this news was published, CLLS gained 20.13%, reflecting a significant positive market reaction. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. The stock closed at $4.59 on that trading session. This price movement added approximately $56M to the company's valuation, bringing the market cap to $332M at that time. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Oct. 07, 2025 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares
in the capital
Total number of voting
rights
09/30/2025100,325,22989,413,272


For further information on Cellectis, please contact:

Media contacts:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment


FAQ

What are Cellectis's total shares and voting rights as of 09/30/2025 (CLLS)?

As of 09/30/2025, Cellectis reports 100,325,229 total shares and 89,413,272 total voting rights.

Which listing and ISIN apply to Cellectis in the 09/2025 share capital update?

Cellectis is listed on Euronext Growth with ISIN FR0010425595.

Where can investors get more information about Cellectis share capital (CLLS)?

Investors can contact Arthur Stril, Chief Financial Officer & Chief Business Officer, via the provided investor relations email.

Does the 09/30/2025 release for Cellectis indicate any capital changes or transactions?

The publication only provides the total number of shares and voting rights as of the date and does not state any specific transactions.

Which regulatory article governs Cellectis's monthly share capital disclosure?

The disclosure is made under Article 223-16 of the General Regulation of the French financial markets authority.

Who are the media contacts listed in Cellectis's September 2025 voting rights notice?

Media contacts listed include Pascalyne Wilson and Patricia Sosa Navarro, with phone numbers and an email for media inquiries.
Cellectis

NASDAQ:CLLS

CLLS Rankings

CLLS Latest News

CLLS Latest SEC Filings

CLLS Stock Data

467.52M
72.33M
3.85%
18.77%
0.21%
Biotechnology
Healthcare
Link
France
Paris